M&A Deal Summary

Fujirebio Acquires ADx NeuroSciences

On June 23, 2022, Fujirebio acquired life science company ADx NeuroSciences for 40M EUR

Acquisition Highlights
  • This is Fujirebio’s 1st transaction in the Life Science sector.
  • This is Fujirebio’s largest (disclosed) transaction.
  • This is Fujirebio’s 1st transaction in Belgium.

M&A Deal Summary
Date 2022-06-23
Target ADx NeuroSciences
Sector Life Science
Buyer(s) Fujirebio
Deal Type Add-on Acquisition
Deal Value 40M EUR

Target

ADx NeuroSciences

Gent, Belgium
ADx NeuroSciences is an R&D-driven company specializing in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production, and worldwide commercialization of novel biomarkers. These collaborations result in new diagnostic assays that support the development of promising drugs either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays are used in neurodegenerative diseases like Alzheimer’s disease and Parkinson’s and can be applied to a variety of platforms for research up to IVD use. ADx NeuroSciences was formed in 2011 and is based in Gent, Belgium.

Search 200,066 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Fujirebio

Tokyo, Japan
Category Company
Founded 1950
Sector Medical Products
DESCRIPTION

Fujirebio focused on developing and marketing CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, over 25 years ago. It remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools. Fujirebio was formed in 1950 and is based in Tokyo, Japan.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Belgium) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal